Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients
نویسندگان
چکیده
منابع مشابه
Differences in Erythrocyte Index and Hyporesponsiveness to Erythropoiesis in Hemodialysis Patients Treated with Different Erythropoiesis-Stimulating Agents
The majority of patients undergoing hemodialysis have anemia due to decreased production of erythropoietin. This condition is referred to as renal anemia, and is a type of normocytic and normochromic anemia. Renal anemia contributes to a worsening of quality of life (QOL) and has a poor prognosis for survival. Clinical use of erythropoiesis-stimulating agents (ESAs) has markedly improved the QO...
متن کاملAn economic evaluation of erythropoiesis-stimulating agents in CKD.
BACKGROUND The objective was to determine the cost-effectiveness of treating anemic patients with chronic kidney disease (CKD) with erythropoiesis-stimulating agents (ESAs) to a low (9-10.9 g/dL), intermediate (11-12 g/dL), or high (> 12 g/dL) hemoglobin level target compared with a strategy of managing anemia without ESAs. STUDY DESIGN Cost-utility analysis. SETTING & PARTICIPANTS Publicly...
متن کاملAn economic evaluation of erythropoiesis-stimulating agents in CKD
CRD summary The study assessed the cost-effectiveness of treating non-dialysis and dialysis patients with chronic kidney disease with erythropoiesis-stimulating agents (ESAs) to a low, intermediate or high haemoglobin level target. The authors concluded that targeting ESA treatment to high haemoglobin levels was not associated with overall clinical benefit and resulted in considerable additiona...
متن کاملEvaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia.
BACKGROUND Inadequate anaemia correction (haemoglobin (Hb) <11 g/dl without receiving an erythropoiesis-stimulating agent (ESA) is common in pre-dialysis patients, but little is known about its determinants. We used data from the French end-stage renal disease (ESRD) registry to investigate these determinants and the patients' anaemia status 1 year after starting dialysis. METHODS Pre-dialysi...
متن کاملTreatment of renal anemia: Erythropoiesis stimulating agents and beyond
Anemia, complicating the course of chronic kidney disease, is a significant parameter, whether interpreted as subjective impairment or an objective prognostic marker. Renal anemia is predominantly due to relative erythropoietin (EPO) deficiency. EPO inhibits apoptosis of erythrocyte precursors. Studies using EPO substitution have shown that increasing hemoglobin (Hb) levels up to 10-11 g/dL is ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2012
ISSN: 1460-2385,0931-0509
DOI: 10.1093/ndt/gfs007